anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly recommended for perioperative opioid-sparing multimodal analgesic treatments. Concerns regarding the potential for serious adverse events (SAEs) associated with perioperative NSAID treatment are especially relevant following gastrointestinal surgery. We assessed the risks of SAEs with perioperative NSAID treatment in patients undergoing gastrointestinal surgery.
METHODS: We conducted a systematic review of randomised clinical trials assessing the harmful effects of NSAIDs versus placebo, usual care or no intervention in patients undergoing gastrointestinal surgery. The primary outcome was an incidence of SAEs. We systematically searched for eligible trials in five major databases up to January 2024. We performed risk of bias assessments to account for systematic errors, trial sequential analysis (TSA) to account for the risks of random errors, performed meta-analyses using R and used the Grading of Recommendations Assessment, Development and Evaluation framework to describe the certainty of evidence.
RESULTS: We included 22 trials enrolling 1622 patients for our primary analyses. Most trials were at high risk of bias. Meta-analyses (risk ratio 0.78; 95% confidence interval [CI] 0.51-1.19; I2 = 4%; p = .24; very low certainty of evidence) and TSA indicated a lack of information on the effects of NSAIDs compared to placebo on the risks of SAEs. Post-hoc beta-binomial regression sensitivity analyses including trials with zero events showed a reduction in SAEs with NSAIDs versus placebo (odds ratio 0.73; CI 0.54-0.99; p = .042).
CONCLUSION: In adult patients undergoing gastrointestinal surgery, there was insufficient information to draw firm conclusions on the effects of NSAIDs on SAEs. The certainty of the evidence was very low.
The present invention discloses a Chinese medicine composition and relates to a preparation method and a quality control method for the composition at the same time. The Chinese medicine composition contains cornu caprae hircus, cape jasmine fruit, thunberg fritillary bulb, common selfheal fruit-spike, figwort root, schisandrae, bupleurum root, etc. and is used for treating hyperthyroidism symptoms. The preparation method of the present invention comprises the steps that the cornu caprae hircus is powdered into fine powder, and after soaked in water, the fine powder is decocted and filtered; the filter dregs, the common selfheal fruit-spike, the figwort root and the bupleurum root are decocted in water, decompressed, concentrated, etc.; the cape jasmine fruit, the schisandrae and the thunberg fritillary bulb are extracted through ethanol refluxing, extract liquid and the medicinal liquid are concentrated and dried into a dry ointment, and then the cornu caprae hircus extract is added so as to obtain the Chinese medicine composition. The preparation realized by the preparation method and the quality control method of the present invention has the advantages of accurate curative effect and controllable quality.
BACKGROUND: This study investigates the mobilization of cranial nerves in the upper clival region to improve surgical approaches. Cadaveric specimens (n = 20) were dissected to examine the oculomotor, trochlear, and abducens nerves. Dissection techniques focused on the nerves' intradural course and their relationship to surrounding structures.
METHODS: Pre-dissection revealed the nerves' entry points into the clival dura and their proximity to each other. Measurements were taken to quantify these distances. Following intradural dissection, measurements were again obtained to assess the degree of nerve mobilization.
RESULTS: Dissection showed that the abducens nerve takes three folds during its course: at the dural foramen, towards the posterior cavernous sinus, and lastly within the cavernous sinus. The trochlear nerve enters the dura and makes two bends before entering the cavernous sinus. The oculomotor nerve enters the cavernous sinus directly and runs parallel to the trochlear nerve. Importantly, intradural dissection increased the space between the abducens nerves (by 4.21 mm) and between the oculomotor and trochlear nerves (by 3.09 mm on average). This indicates that nerve mobilization can create wider surgical corridors for approaching lesions in the upper clivus region.
CONCLUSIONS: This study provides a detailed anatomical analysis of the oculomotor, trochlear, and abducens nerves in the upper clivus. The cadaveric dissections and measurements demonstrate the feasibility of mobilizing these nerves to achieve wider surgical corridors. This information can be valuable for surgeons planning endoscopic or microscopic approaches to lesions in the upper clivus region.
Randomization will only occur after detection of epileptiform activity on EEG. Participants randomized to this arm will be treated with vigabatrin until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on vigabatrin, they will be eligible for Open label vigabatrin. Participants will be followed until 36 months of age.
Methods for producing an enriched reference data map useful for identifying critical factors for the development of a condition of interest are disclosed. The reference data map may be used to assess the risk or likelihood of a condition of interest being realized. In the context of medicine or genetics, the methods of the invention may be used to produce a risk assessment roadmap useful for identifying elements (biomolecular constructs, biological interactions, and biological pathways) that are critical to the development of a particular disease or syndrome. The roadmap may be consulted to design treatment methods having the greatest likelihood of successfully treating or preventing the development of a disease or syndrome. Also disclosed are methods for using such a risk assessment roadmap to evaluate a specific configuration of elements for determining the changes in the configuration of elements that will result in the achievement or the avoidance of a defined condition of interest. In the context of medicine or genetics, the invention provides methods for determining the susceptibility of an individual or group of individuals to develop a particular disease or syndrome utilizing biological data of the individual or group and assessing the level of risk by referencing a risk assessment roadmap prepared according to the disclosure herein. Uncertainty in diagnosis is minimized or eliminated by these methods, and the targets, interactions, and pathways most likely to be critical for disease development, and so representing the best intervention points for treatment or prevention of the disease or syndrome, are identified.
IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
The investigators allocate 59 patients in this arm. It serves as the control group, who receives local infiltration anaesthesia.
ARID1B-related disorders constitute a clinical continuum, from classic Coffin-Siris syndrome to intellectual disability (ID) with or without nonspecific dysmorphic features. Here, we describe an 11-year-old boy with an ARID1B mutation whose phenotype changed from severe developmental delay and ID to a complex neurodevelopmental disorder with multidimensional impairments, including normal intelligence despite heterogeneous IQ scores, severe motor coordination disorder, oral language disorder and attention-deficit/hyperactivity disorder. Phenotypic changes occurred after early intensive remediation and paralleled the normalization of myelination impairments, as evidenced by early brain imaging. WHAT THIS PAPER ADDS?: This report describes a 10-year multidisciplinary follow-up of a child with an ARID1B mutation who received early intensive remediation and whose phenotype changed during development. Clinical improvement paralleled the normalization of myelination impairments. This case supports a dimensional approach for complex neurodevelopmental disorders.
Investigators anticipate that counselors in SAU will see youth in the study for brief, periodic sessions and/or will refer youth for treatment in the community. Counselors will be permitted to see the adolescents as often as they would like throughout the course of the study (up to 15-months post-baseline). Investigators will ask counselors to complete a form each time they see a teen, noting the length of the session, whether the session was scheduled or not, and the topics discussed.
Sorghum anthracnose caused by the fungus Colletotrichum sublineola (Cs) is a damaging disease of the crop. Here, we describe the identification of ANTHRACNOSE RESISTANCE GENES (ARG4 and ARG5) encoding canonical nucleotide-binding leucine-rich repeat (NLR) receptors. ARG4 and ARG5 are dominant resistance genes identified in the sorghum lines SAP135 and P9830, respectively, that show broad-spectrum resistance to Cs. Independent genetic studies using populations generated by crossing SAP135 and P9830 with TAM428, fine mapping using molecular markers, comparative genomics and gene expression studies determined that ARG4 and ARG5 are resistance genes against Cs strains. Interestingly, ARG4 and ARG5 are both located within clusters of duplicate NLR genes at linked loci separated by ~1 Mb genomic region. SAP135 and P9830 each carry only one of the ARG genes while having the recessive allele at the second locus. Only two copies of the ARG5 candidate genes were present in the resistant P9830 line while five non-functional copies were identified in the susceptible line. The resistant parents and their recombinant inbred lines carrying either ARG4 or ARG5 are resistant to strains Csgl1 and Csgrg suggesting that these genes have overlapping specificities. The role of ARG4 and ARG5 in resistance was validated through sorghum lines carrying independent recessive alleles that show increased susceptibility. ARG4 and ARG5 are located within complex loci displaying interesting haplotype structures and copy number variation that may have resulted from duplication. Overall, the identification of anthracnose resistance genes with unique haplotype stucture provides a foundation for genetic studies and resistance breeding.
Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (IKDE) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium. The therapeutic factors include small interfering RNAs, tumoricidal proteins, DNA molecules, or a combination thereof. The system provides direct killing of tumor cells and alters the tumor microenvironrment by expressing anti-angiogenic factors and cytokines in intracellular and/or extracellular environments. Also provided arc- methods of using natural exosomes comprising cargoes obtained from the bacterially infected cells. The bacteria-vector system is useful tor many types at tumor and cancer as well as recombinant vaccines. The method causes significant regression of tumor and prolongs survival of tumor-bearing mice and subject without detectable systemic toxicity.
The invention relates to a flavone compound being extracted from dicranopteris pedata and having a prostatic cancer resistant effect and a preparation method of the flavone compound. The method comprises the following steps of: extracting the dicranopteris pedata by using ethanol, concentrating under reduced pressure, extracting with petroleum ether, chloroform and ethyl acetate sequentially, concentrating the ethyl acetate extract under reduced pressure, purifying the concentrate to separate out flavone, and drying at a low temperature in vacuum to obtain dicranopteris pedata flavone powder. The flavone powder is subjected to apoptosis experiments of in-vitro prostatic PC-3 cancer cells. The experimental results show that the flavone has a significant inhibiting effect on the prostatic PC-3 cancer cells and has an obvious dose-effect relationship. Fluorescence analysis shows that the flavone has a significant inhibiting effect on the transcription factor NF-kB. The compound also has the advantages of rich resources, simple equipment, high product extraction rate and solvent recyclability. Therefore, the compound has a good medicinal and functional food development prospect.
Hair cleansing conditioners which, relative to the weight of the total compositions, contains 0.01 to 10 wt.% of at least one polyether-modified polysiloxane, 0.01 to 10 wt.% of at least one amino-functional silicone, 0.01 to 15 wt.% of at least one hydrophobically-modified starch compound, and 0.10 to 30 wt.% of at least one amphoteric tenside (surfactant). The compositions may also contain a cationic surfactant but preferably the compositions contain no anionic surfactants. In an embodiment, the polyether-modified polysiloxane is PEG-12 dimethicone, the amino-functional silicone is amodimethicone, the hydrophobically modified starch is hydroxypropyl starch phosphate and the amphoteric surfactant is cocamidopropylbetain. In some embodiments a C12-C14 alcohol, such as cetyl or stearyl alcohol is present. In other embodiments the composition is supplied as an aerosol. Methods for using the compositions are also disclosed.
There has been a steady increase in the rate of Caesarean births in Canada and worldwide. Almost half of all primary caesarean sections are performed for labour dystocia - when labour is abnormally slow or when there is no further progression in cervical dilatation. When dystocia occurs, oxytocin is used to increase the frequency and intensity of uterine contractions, with the goal of achieving full cervical dilatation and a vaginal birth. The actual dose required to produce a clinical response (progressive cervical dilatation) varies greatly from patient to patient. There is a wide range of oxytocin regimens currently in use. They may be broadly categorized as being of two types: 1) those involving a gradual titration of oxytocin dose (or 'low dose') and 2) those with accelerated oxytocin titration (also called 'high dose').

In fact, the frequently used terms 'low dose' and 'high dose' are to a certain extent misnomers. Both protocols titrate oxytocin dose to achieve the desired 'physiological frequency' of uterine contractions (usually 4 to 5 contractions in a 10 minute interval) that are normally sufficient to result in progressive labour. Thus, the target dose should, theoretically, be identical and independent of the rate of increase of oxytocin. These protocols differ mainly in the rate at which the desired physiologic response is achieved. While most patients achieve a response to stimulation at oxytocin concentrations between 4 and 10 mU per minute, a proportion of nulliparae require higher doses of oxytocin. Accelerated titration protocols are also frequently associated with a higher maximum concentration of oxytocin. While, most Canadian birthing centres currently follow a 'gradual titration' or 'low dose' protocol, there is evidence that 'accelerated titration' or 'high dose' protocols may be more effective in correcting dystocia and in preventing caesarean section. It is postulated that by more rapidly progressing to the required therapeutic dose, cervical dilatation is achieved more rapidly, the likelihood of a spontaneous vaginal birth is increased, and the risk of occurrence of complications resulting from prolonged labour (such as infection and maternal fatigue) is reduced.
A method of determining and treating disordered tissue in a patient incites energy signal generation from disordered tissue. An energy sensor structure obtains an energy signal from tissue of a patient. The obtained energy signal is compared in a processor circuit to a known energy signal of the same tissue under normal functioning of the tissue. The tissue is identified as disordered tissue when the comparing step determines that the obtained energy signal is different from the known energy signal. The disordered tissue is localized within the patient via the energy signal. A bodily disorder caused by the localized disordered tissue is diagnosed by an AI module. The bodily disorder is then treated.
Myocardial infarction (MI) is a leading cause of death globally. Stem cell therapy is considered a potential strategy for MI treatment. Transplantation of classic stem cells including embryonic, induced pluripotent and cardiac stem cells exhibited certain repairing effect on MI via supplementing cardiomyocytes, however, their clinical applications were blocked by problems of cell survival, differentiation, functional activity and also biosafety and ethical concerns. Here, we introduced human amniotic epithelial stem cells (hAESCs) featured with immunomodulatory activities, immune-privilege and biosafety, for constructing a stem cell cardiac patch based on porous antioxidant polyurethane (PUR), which demonstrated decent hAESCs compatibility. In rats, the administration of PUR-hAESC patch significantly reduced fibrosis and facilitated vascularization in myocardium after MI and consequently improved cardiac remodeling and function. Mechanistically, the patch provides a beneficial microenvironment for cardiac repair by facilitating a desirable immune response, paracrine modulation and limited oxidative milieu. Our findings may provide a potential therapeutic strategy for MI.
Attention Deficit Disorders, Narcolepsy

Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.

Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Special Diagnostic Considerations

Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources.

Characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate-to-severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.

Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms.
The invention relates to a process for the production of thyroglobulin, which is used in the treatment of hypothyroidism, from hog thyroid glands. Ground hog thyroid glands are subjected to saline digestion to produce a thyroglobulin extract. The extract is precipitated by pH adjustment and then heated to a denaturing temperature. The denatured precipitated thyroglobulin solution is subjected to a separation step to produce crude wet thyroglobulin solids. The crude thyroglobulin solids are defatted and dewatered by solvent extraction. The resultant defatted thyroglobulin product can then be further worked up, for example, by drying, milling, and screening, to produce a powdered product. In order to achieve a final product having a T4/T3 ratio of 2.6-3.4 and upon proteolysis a minimum of 0.7  mu g/mg of levothyronine and 2.1  mu g/mg of liothyronine, the time periods for the precipitating, denaturing, and/or defatting steps are carefully controlled so that the T4/T3 ratio is within this desired range.
The safety and effectiveness of bromocriptine for the treatment of prolactin-secreting pituitary adenomas have been established in patients age 16 to adult. No data are available for bromocriptine use in pediatric patients under the age of 8 years. A single 8-year-old patient treated with bromocriptine for a prolactin-secreting pituitary macroadenoma has been reported without therapeutic response.

The use of bromocriptine for the treatment of prolactin-secreting adenomas in pediatric patients in the age group 11 to under 16 years is supported by evidence from well-controlled trials in adults, with additional data in a limited number (n=14) of children and adolescents 11 to 15 years of age with prolactin-secreting pituitary macro- and microadenomas who have been treated with bromocriptine. Of the 14 reported patients, 9 had successful outcomes, 3 partial responses, and 2 failed to respond to bromocriptine treatment. Chronic hypopituitarism complicated macroadenoma treatment in 5 of the responders, both in patients receiving bromocriptine alone and in those who received bromocriptine in combination with surgical treatment and/or pituitary irradiation.

Safety and effectiveness of bromocriptine in pediatric patients have not been established for any other indication listed in the INDICATIONS AND USAGE section.
PURPOSE:To provide the titled agent containing dihydrochikusetsu-saponin III as a main component, and having blood activation effect. CONSTITUTION:A respiratory complement having blood activation effect is prepared by using dihydrochikusetsu-saponin III of formula as a main component. Preferably dose in an urgent blood activation in flooding is 15-25mg/dose for intravenous injection and 50-100mg/dose for oral administration, and <=3 doses a day. The agent is effective to improve the function of blood in the case of flooding in major operation, etc., and to recover the fatigue quickly. It is also useful for the improvement of intractable diseases such as rheumatism, neutralgia, etc. by continuous use for a long period, and for the maintenance of health. The main component can be prepared by crushing the rhizome of Panax japonicus, extracting with hot water containing 50% of methanol, concentrating the extract liquid, extracting the concentrated aqueous solution of the extract with n-butanol, and subjecting the resultant extract e.g. to counter-current partition, etc.
The method for estimating the changes in the parameters of intracardiac hemodynamics in the patients with ischemic heart disease with concomitant diabetes mellitus type 2 provides for laboratory and clinical research. In the setting of the basic therapy, echocardiography is provided with estimation of the parameters of the heart patterns and intracardiac hemodynamics. End-diastolic and end-systolic sizes of the left ventricle, the diameter of the left and right atrium and right ventricle, the thickness of the interventricular septum and posterior wall of the left ventricle are measured. The parameters of the diastolic function of the left and right ventricles are determined based on the analysis of transmitral and transtricupsidal flow. The maximal velocity of early and late peaks of the diastolic filling of the ventricles and their relationship are assessed. The results are compared with the control. The changes of the parameters are indicative of the changes in intracardiac hemodynamics.